Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg Fixed Dose Combination Film-coated Tablet Under Fed and Fasting Conditions in Healthy Volunteers

A Randomized, Open-label, Single-dose, Two-way Crossover Study to Investigate Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg Fixed Dose Combination Film-coated Tablet under Fed and Fasting Conditions in Healthy Volunteers

开始日期2022-01-01

申办/合作机构

LG Chem Ltd.

NCT04317703

/ Completed临床1期

A Randomized, Open-label, Single-dose, Two-way Crossover Bioequivalence Study of Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg) and Coadministration of Zemiglo Tablet 50 mg (Gemigliptin 50 mg) and Glucophage® XR 1000 mg (Metformin Hydrochloride Prolonged Release 1000 mg) Under Fasting Conditions in Healthy Volunteers

To determine and compare the rate and extent of absorption of gemigliptin/metformin hydrochloride sustained release 50/1000 mg FDC tablet (Zemimet® SR Tab. 50/1000 mg) and coadministration of corresponding dose of gemigliptin 50 mg (Zemiglo Tablet 50 mg) and metformin hydrochloride 1000 mg prolonged release (Glucophage XR 1000 mg) as individual tablet in healthy subjects under fasting conditions

开始日期2020-08-19

申办/合作机构

LG Chem Ltd.

NCT04255238

/ Unknown status临床3期

A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group, Phase 3 Trial to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Compared to add-on Therapy With Gemigliptin 50 mg in Combination With Metformin or Dapagliflozin 10 mg in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

The objective of this study is to evaluate the efficacy and safety of dual add-on therapy with Gemigliptin 50 mg and Dapagliflozin 10 mg added to Metformin compared to add-on therapy with Gemigliptin 50 mg in combination with Metformin or Dapagliflozin 10 mg in combination with Metformin in patients with type 2 diabetes mellitus who have inadequate glycemic control on metformin alone

开始日期2020-06-30

申办/合作机构

LG Chem Ltd.

100 项与吉格列汀酒石酸盐相关的临床结果

登录后查看更多信息

100 项与吉格列汀酒石酸盐相关的转化医学

登录后查看更多信息

100 项与吉格列汀酒石酸盐相关的专利（医药）

登录后查看更多信息

148

项与吉格列汀酒石酸盐相关的文献（医药）

2024-12-01·Sustainable Chemistry and Pharmacy

Efficient integration of analytical quality-by-design and tri-hued HPLC-DAD approach for synchronized assessment of gemigliptin and rosuvastatin in their fixed-dose pills: Application to stability study

作者: Mohyeldin, Sara M. ; Talaat, Wael ; Kamal, Miranda F. ; Daabees, Hoda G.

Life-threatening atherosclerotic cardiovascular disorder is a well-recognized risk among diabetics, which is clin. ascribed to their unbalanced plasma lipoproteins.Gemigliptin-Rosuvastatin is a recently introduced polytherapy prescribed for the management of diabetic dyslipidemia.Currently, the main focus of several analysts is to design more ecol. friendly sustainable approaches for pharmaceutical anal.In this context, an innovative tri-hued (green, blue, and white) stability-indicating HPLC-DAD approach was developed to concurrently quantify Gemigliptin and Rosuvastatin polypills.Consequently, a strategic integration between anal. quality-by-design and green/white anal. chem. principles was specifically designed to optimize efficiency and practicality while minimizing ecol. burden.Two exptl. designs, namely two-level fractional factorial and Box-Behnken designs, were employed for screening and optimization procedures, resp.Optimal separation was attained utilizing an Agilent HC-C18 column in conjunction with a mobile phase consisting of acetonitrile and 10 mM sodium dihydrogen phosphate buffer, pH 3 (60:40 volume/volume), eluted in an isocratic manner at a 1 mL/min flow rate.Both analytes exhibited good linearities within the concentration range of 0.5-100μg/mL.Furthermore, stability studies were conducted on both drugs in response to variable stress degradation scenarios.Fortunately, the adopted approach was well-suited to resolve the studied drugs from their resp. degradants, thereby verifying the method's stability-indicating power.Tri-hued evaluation for the implemented approach was performed via up-to-date metrics, specifically, the Anal. Eco-scale, AGREE, Blue Applicability Grade Index, and RGB 12.Ultimately, our adopted stability-indicating HPLC approach exhibited great sensitivity, specificity, applicability, and rapidity as well as being ecol. sound.It is worth noting that this is the first stability-indicating HPLC approach for simultaneous assessment of the studied drugs.

2024-11-01·BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Gemigliptin mitigates TGF-β-induced renal fibrosis through FGF21-mediated inhibition of the TGF-β/Smad3 signaling pathway

Article

作者: Byun, Jun-Kyu ; Jung, Gwon-Soo

Fibroblast growth factor 21 (FGF21), a well-known regulator of metabolic disorders, exhibits the potential to prevent renal fibrosis by negatively regulating the transforming growth factor β (TGF-β)/Smad3 signaling pathway. Gemigliptin and other dipeptidyl peptidase-4 inhibitors are frequently used for the management of patients with type 2 diabetes. However, the protective effect of gemigliptin against renal fibrosis, particularly its potential to upregulate the expression of FGF21, remains incompletely understood. This study assessed the renoprotective effects of gemigliptin against TGF-β-induced renal fibrosis by enhancing the expression of FGF21 in the cultured human proximal tubular epithelial cell line HK-2. Treatment with FGF21 effectively prevented TGF-β-induced renal fibrosis by attenuating the TGF-β/Smad3 signaling pathway. Similarly, gemigliptin exhibited protective effects against TGF-β-induced renal fibrosis by mitigating TGF-β/Smad3 signaling through the upregulation of FGF21 expression. However, the protective effects of gemigliptin were blocked when FGF21 expression was knocked down in TGF-β-treated HK-2 cells. These results indicate that gemegliptin has the potential to exhibit protective effects against TGF-β-induced renal fibrosis by elevating FGF21 expression levels in cultured human proximal tubular epithelial cells.

2024-09-01·DIABETES OBESITY & METABOLISM

Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study

Article

作者: Kim, Kyoung‐Ah ; Hwang, You‐Cheol ; Park, Cheol‐Young ; Won, Jong Chul ; Kang, Jun Goo ; Yoo, Hye Jin ; Park, Kyong Soo ; Chon, Suk ; Moon, Shin Je ; Cho, Ho Chan ; Kim, Tae Nyun ; Cho, Eunjoo ; Han, Kyung Ah ; Kim, Jeongyun ; Choi, Sung Hee

Abstract:

Aim:

To evaluate the efficacy and safety of gemigliptin and dapagliflozin dual add‐on therapy (GEMI + DAPA) to metformin in type 2 diabetes (T2D) patients who had inadequate glycaemic control on metformin alone, compared with a single add‐on of either gemigliptin (GEMI) or dapagliflozin (DAPA) to metformin.

Materials and Methods:

In this randomized, double‐blind, double‐dummy, active‐controlled, parallel‐group, phase 3 study, 469 T2D patients treated with a stable dose of metformin for 8 weeks or longer were randomized to receive GEMI + DAPA (n = 157) and either GEMI (n = 156) or DAPA (n = 156). The primary endpoint was change in HbA1c levels from baseline at week 24.

Results:

Baseline characteristics including body mass index and T2D duration were similar among groups. At week 24, the least square mean changes in HbA1c from baseline were −1.34% with GEMI + DAPA, −0.90% with GEMI (difference between GEMI + DAPA vs. GEMI −0.44% [95% confidence interval {CI}: −0.58% to −0.31%], P < .01) and −0.78% with DAPA (difference between GEMI + DAPA vs. DAPA −0.56% [95% CI: −0.69% to −0.42%], P < .01). Both upper CIs were less than 0, demonstrating the superiority of GEMI + DAPA for lowering HbA1c. The rates of responders achieving HbA1c less than 7% and less than 6.5% were greater with GEMI + DAPA (84.9%, 56.6%) than with GEMI (55.3%, 32.2%) and DAPA (49.3%, 15.3%). The incidence rate of adverse events was similar across groups, with low incidence rates of hypoglycaemia, urinary tract infection and genital infection.

Conclusions:

These results suggest that the addition of GEMI + DAPA to metformin as triple combination therapy was effective, safe and well‐tolerated, especially for T2D patients who experienced poor glycaemic control on metformin alone.

项与吉格列汀酒石酸盐相关的新闻（医药）

2023-11-24

·SYNAPSE

What are DPP-4 inhibitors and how do you quickly get the latest development progress?

Dipeptidyl peptidase-4 (DPP-4) is an enzyme found in the human body that plays a crucial role in regulating glucose metabolism. It is primarily expressed in the pancreas, intestines, and immune cells. DPP-4 is responsible for breaking down incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are released after a meal to stimulate insulin secretion and reduce blood sugar levels. By inhibiting DPP-4 activity, pharmaceutical drugs can prolong the action of these incretin hormones, leading to increased insulin release, improved glycemic control, and potential therapeutic benefits for individuals with type 2 diabetes. Several dozens of DPP-4 inhibitors have been introduced to the market, with sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin being available in domestic markets. DPP-4 inhibitors can be combined with multiple antidiabetic drugs to form fixed-dose combinations, among which, the combinations with metformin are most common. The currently available DPP-4 inhibitor-metformin fixed-dose combinations in the domestic market include sitagliptin/metformin tablets, vildagliptin/metformin tablets, saxagliptin/metformin extended-release tablets, linagliptin/metformin tablets. DPP-4 inhibitors can be used as monotherapy for type 2 diabetes and can also be combined with other antidiabetic drugs for the treatment of type 2 diabetes. The most commonly combined antidiabetic drugs with DPP-4 inhibitors are metformin, followed by sulfonylureas, thiazolidinediones, and insulin. They can also be used in combination with two other antidiabetic drugs, forming a triple therapy commonly including combinations of DPP-4 inhibitors + metformin + sulfonylureas, DPP-4 inhibitors + metformin + thiazolidinediones, and DPP-4 inhibitors + metformin + insulin. The analysis of the target DPP-4 in the pharmaceutical industry reveals a competitive landscape with several companies focusing on the development of DPP-4 inhibitors. Merck & Co., Inc., Takeda Pharmaceutical Co., Ltd., C.H. Boehringer Sohn AG & Co. KG, LG Chem Ltd., and AstraZeneca PLC are among the companies growing fastest under this target. The primary indication for the approved drugs is diabetes mellitus, type 2. Small molecule drugs are progressing most rapidly, indicating intense competition around the innovative drug. The United States, European Union, Japan, and China are the countries/locations developing fastest under this target, with China showing significant progress. Overall, the target DPP-4 presents opportunities for further research and development in the treatment of diabetes and related indications. Unlocking Blood Sugar Control: The Role of DPP-4 Inhibitors in Type 2 Diabetes ManagementDPP-4 inhibitors, also known as dipeptidyl peptidase-4 inhibitors, are a type of medication used in the treatment of type 2 diabetes. From a biomedical perspective, DPP-4 inhibitors work by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for breaking down incretin hormones in the body. Incretin hormones play a role in regulating blood sugar levels by stimulating the release of insulin and reducing the production of glucagon. By inhibiting DPP-4, these medications increase the levels of incretin hormones, leading to improved blood sugar control. DPP-4 inhibitors are typically taken orally and are often prescribed as an adjunct to diet and exercise in the management of type 2 diabetes. They can be used as monotherapy or in combination with other antidiabetic medications, such as metformin. Some common examples of DPP-4 inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin. These medications have been shown to be effective in lowering blood sugar levels and have a favorable safety profile. It's important to note that DPP-4 inhibitors are not recommended for the treatment of type 1 diabetes or diabetic ketoacidosis. They are primarily used in the management of type 2 diabetes and can help improve glycemic control in individuals with this condition. As with any medication, DPP-4 inhibitors may have potential side effects, and it is essential to consult with a healthcare professional for proper evaluation and monitoring while taking these medications. Catalog of DPP-4 InhibitorsThe currently marketed DPP-4 inhibitors include: Sitagliptin/Metformin HydrochlorideSitagliptinRetagliptin PhosphateGemigliptin/DapagliflozinMetformin Hydrochloride/Sitagliptin HydrochlorideEmpagliflozin/Linagliptin/Metformin HydrochlorideAnagliptin/Metformin HydrochlorideErtugliflozin/Sitagliptin PhosphateGosogliptinEvogliptinFor more information, please click on the image below. What is the purpose of using DPP-4 inhibitors?DPP-4 inhibitors can be used as a mono-drug treatment for type 2 diabetes, or in combination with other glucose-lowering drugs for the treatment of type 2 diabetes. For more information, please click on the image below to log in and search. How can you get the most recent advancements in DPP-4 inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of DPP-4 inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

2023-02-28

·PRNewswire

M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavoglifozin) for Brazil and Mexico

MEXICO CITY, Feb. 28, 2023 /PRNewswire/ -- M8 Pharmaceuticals and Daewoong Pharmaceuticals announced they have signed an exclusive licensing agreement whereby M8 will have the rights to register and commercialize Envlo™ (Enavoglifozin) for Brazil and Mexico. The novel drug Envlo™ (Enavoglifozin) is a SGLT2 (sodium glucose cotransporter 2) inhibitor type diabetes treatment, and last November, it has received a regulatory approval in South Korea. Phase 3 clinical trials have been performed on type 2 diabetes patients and its results demonstrated excellent effects in dropping blood sugar level drop. The safety of Envlo™ has been confirmed and proven to show equal medicinal effect with only 0.3mg, which is 1/30 of the amount of existing SGLT2 inhibitor and has been shown to be a promising new treatment option for patients and prescribers who were unsatisfied with the blood sugar controls. It has been proven to be efficacious as a monotherapy, metformin combined modality therapy and metformin and gemigliptin or other DDP4 (Inhibitors of dipeptidyl peptidase 4) combined modality therapy. During the development of the product, Envlo™ was designated as South Korea's first drug to received a fast-track review in 2020, and is expected to be launched in South Korea by Daewoong in the first half of 2023. The Enavogliflozin monotherapy trial was a placebo-controlled superiority study. The HbA1c decreased in the Enavogliflozin group by approximately 1% over the placebo group, which was statistically significant. In addition, significant improvements were confirmed in weight, blood pressure, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) compared to the placebo group. The two combination trials, Enavogliflozin-Metformin and Enavogliflozin-Metformin-Gemigliptin combination, demonstrated non-inferiority in HbAc1 change compared to dapagliflozin 10 mg and its equivalent combinations. Through this agreement, Daewoong Pharmaceuticals has the plan to accelerate further overseas expansion for Enavogliflozin including China, Saudi Arabia and Russia and expand into 15 countries by 2025 and 50 countries by 2030. M8 Pharmaceuticals continues its commitment of bringing proven and innovative products to Latin American patients, and the agreement reinforces its commitment and capabilities in the area of cardiometabolism. Diabetes affects over 30 million people in Brazil and Mexico, and many of these patients continue to need better therapeutic options to optimize symptom control and improve their quality of live. According to IQVIA, the SGLT2 inhibitor market in Brazil and Mexico exceeds the 470 million USD in value and grows at a rate of more than 20% annually. "We are delighted to continue to strengthen our strategic partnership with Daewoong and see a large opportunity to address the unmet needs of millions of Latin Americans suffering from diabetes, by bringing a product like Envlo™ to the SGLT2 market with the potential to be best-in-class" stated Joel Barlan, M8's CEO. CEO Seng-ho Jeon from Daewoong Pharmaceutical stated "This contract with M8 is an example proving that Daewoong Pharmaceutical's synthetic new drugs such as Fexuclue and Envlo, are recognized as global blockbusters" and "With this contract in Central and South America as the starting point, we expect that the 36th domestically produced new drug Envlo will expand its entry into the global market in the future." About M8 PHARMACEUTICALS M8 is a specialty biopharmaceutical company focused on licensing, marketing and distributing innovative and established therapeutics in Latin America: Brazil and Mexico. We aim to become the preferred pharmaceutical partner for the licensing of high-value innovative and proven therapies across our main therapeutic areas CNS, Respiratory, Cardiometabolic, Immunology, Gastroenterology, Onco-hematology and Rare Diseases. Our mission is to provide the people of Latin America with access to the proven and innovative medicines they need to transform their lives. For further information, please visit: For more information please contact: Joel Barlan Chief Executive Officer T: +52 (55) 4431 2933 [email protected] Rafael Ferrer Vice President of Corporate Development & Strategy T: +1 (305) 299 6998 [email protected] SOURCE M8 Pharmaceuticals

临床3期引进/卖出临床结果快速通道

2022-12-15

·FierceBiotech

Innovent plucks Chinese rights to LG Chem's gout disease treatment in nearly $100M deal

LG Chem's deal with Innovent comes months after the Korea-based company bought Aveo Oncology. Innovent is adding a new late-stage med to its pipeline, buying the Chinese rights to LG Chem’s phase 3 gout disease treatment for nearly $100 million. The agreement, announced Thursday, gives Innovent exclusive Chinese rights to tigulixostat, a non-purine xanthine oxidase inhibitor that manages the buildup of uric acid in patients with gout. In return, the company is paying LG Chem $10 million upfront with $85.5 million in biobucks waiting in the wings. Tigulixostat lands in Innovent’s lap with the wind in its sails after beating out both placebo and Takeda’s Uloric in uric acid reductions during a phase 2 study. LG Chem launched a phase 3 trial this quarter with the expectation of recruiting 3,000 patients across the U.S., Europe and other countries. The approval potential of the med is particularly tantalizing to Innovent given that the prevalence of hyperuricemia in China could be as high as 13.3% of the population. Another study conducted by China’s CDC found that the prevalence among adults is 11.1%. The med slides into a portfolio that includes eight approved meds in China, primarily in oncology, but a relatively thin slate of metabolic treatments. As for LG Chem, the rights handoff continues a string of deals after agreeing to buy Aveo Oncology and its approved kidney cancer drug in October for $566 million. The company noted that one of the benefits to partnering with Innovent was getting a foot in the door to the Chinese market. LG Chem’s only approved med is Zemiglo, a Type 2 diabetes treatment greenlighted for use in Korea and Thailand. Beyond tigulixostat, the company is working on treatments for nonalcoholic steatohepatitis, obesity and Type 1 diabetes.

临床3期引进/卖出上市批准临床2期并购

100 项与吉格列汀酒石酸盐相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	吉格列汀酒石酸盐	A10BH06	DB12412

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	韩国	LG Chem Ltd.	2012-06-27
2型糖尿病	韩国	LG Life Sciences Ltd.	2012-06-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非胰岛素依赖型糖尿病2	临床3期	-	LG Life Sciences Ltd.	2016-10-17
糖尿病	临床1期	美国	LG Life Sciences Ltd.	2009-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SOLUTION 2 Study (ADA2023)	N/A	追加	469	Gemigliptin and Dapagliflozin	淵膚齋憲遞鑰廠鬱廠淵(顧窪築鬱顧廠鏇膚鑰網) = 壓餘簾顧醖顧繭製壓積糧繭構餘築憲膚範壓構 (蓋壓構顧蓋網壓繭窪鏇 )	积极	2023-06-20
				Gemigliptin	淵膚齋憲遞鑰廠鬱廠淵(顧窪築鬱顧廠鏇膚鑰網) = 構網醖鑰齋鏇範積淵鹹糧繭構餘築憲膚範壓構 (蓋壓構顧蓋網壓繭窪鏇 )
NCT05663736 (Pubmed)	临床4期	2型糖尿病	-	Gemigliptin	窪廠獵觸膚簾糧窪齋膚(網餘積遞衊製範願獵築) = Gemigliptin induced favorable changes in body composition 憲鬱憲廠鬱憲窪鬱築獵 (醖憲鬱獵齋餘憲顧膚獵 )	-	2023-04-12
				Glimepiride
FC 092 (ERA2021)	N/A	糖尿病肾病 hemoglobinA1C \| serum bone alkaline phosphatase \| urine neutrophil gelatinase-associated lipocalin (NGAL)/Cr ... 更多	201	Gemigliptin 50 mg	廠網壓築簾網醖壓觸膚(衊壓憲窪願糧憲遞範鬱) = 夢網積襯構襯餘網構網鹹觸繭網選鏇艱蓋蓋艱 (壓壓鬱齋憲艱觸襯顧醖 )	积极	2021-05-29
				Placebo	廠網壓築簾網醖壓觸膚(衊壓憲窪願糧憲遞範鬱) = 餘衊製壓遞鏇築網廠製鹹觸繭網選鏇艱蓋蓋艱 (壓壓鬱齋憲艱觸襯顧醖 )
NCT02290301 (OPTIMUS, Pubmed \| Sci Rep)	N/A	2型糖尿病	5,179	Gemigliptin	廠構顧糧網襯醖艱廠簾(艱衊蓋醖鑰獵網鑰餘範) = 鹽選遞製願遞鏇鏇壓製積範齋鹽積鏇繭獵夢衊 (鏇鹽積顧壓鹽窪夢廠獵 ) 更多	-	2020-11-04
NCT02831361 (ZEUS II, Pubmed) 人工标引	临床3期	2型糖尿病	283	gemigliptin	艱衊艱壓餘積顧選憲襯(醖淵範鹽淵觸淵憲簾鹹): difference = -0.7 (95% CI, -0.9 ~ -0.4), P-Value = <0.0001 更多	积极	2020-01-01
				Placebo
NCT01990469 (TROICA, Pubmed \| Diabetes Obes Metab) 人工标引	临床3期	2型糖尿病	219	gemigliptin	鹹鑰鏇構顧鬱膚構蓋遞(夢糧憲壓簾齋壓窪獵獵) = 鬱觸觸鹽選膚鹹構願鏇願淵憲餘築繭淵艱窪艱 (壓構壓獵獵遞齋選積鏇 ) 更多	积极	2017-05-01
				Placebo	鹹鑰鏇構顧鬱膚構蓋遞(夢糧憲壓簾齋壓窪獵獵) = 憲餘鑰繭憲艱衊築糧窪願淵憲餘築繭淵艱窪艱 (壓構壓獵獵遞齋選積鏇 ) 更多
ASN2016	N/A	阿霉素的毒性 DPP-IV \| GLP-1 \| Bax/Bcl-2 ratio ... 更多	-	Adriamycin	醖夢遞顧廠糧遞鬱糧觸(衊憲獵醖網蓋艱衊齋淵) = 襯憲窪鏇網選獵製衊壓鬱艱憲淵鏇齋夢齋製願 (糧願淵簾範淵壓簾艱鏇 ) 更多	积极	2016-11-15
				Adriamycin+Gemigliptin	醖夢遞顧廠糧遞鬱糧觸(衊憲獵醖網蓋艱衊齋淵) = 製襯窪艱壓醖顧蓋淵蓋鬱艱憲淵鏇齋夢齋製願 (糧願淵簾範淵壓簾艱鏇 ) 更多
NCT01968044 (GUARD study, EASD2016)	临床3期	2型糖尿病 eGFR	-	Gemigliptin	襯鏇蓋積淵艱積蓋製膚(壓齋鹹鹽蓋餘構顧網遞) = 構遞製獵齋選製築艱觸蓋選簾築獵齋醖遞鏇衊 (廠獵齋廠製鹽簾鹽選壓, 0.14) 更多	积极	2016-09-13
				Placebo	襯鏇蓋積淵艱積蓋製膚(壓齋鹹鹽蓋餘構顧網遞) = 簾獵積糧網選鏇夢憲廠蓋選簾築獵齋醖遞鏇衊 (廠獵齋廠製鹽簾鹽選壓, 0.14)
NCT01990469 (EASD2016)	临床3期	2型糖尿病追加	-	Gemigliptin 50 mg q.d	網艱遞襯構壓選憲繭壓(衊網廠齋繭製艱選製鹽) = 憲選艱積蓋襯蓋鏇衊願夢願獵壓憲積壓選窪選 (積襯鑰網壓窪窪製製築, 0.17)	积极	2016-09-13
				Placebo	網艱遞襯構壓選憲繭壓(衊網廠齋繭製艱選製鹽) = 鹹構壓齋網齋積壓獵觸夢願獵壓憲積壓選窪選 (積襯鑰網壓窪窪製製築, 0.18)
NCT01787396 (EASD2015)	临床3期	2型糖尿病	69	Gemigliptin 50 mg	鬱衊憲網遞鹽艱鬱夢餘(衊憲醖鹽艱簾鹹壓衊襯) = reported more frequently in glimepiride group than in other groups 膚構鹹膚網築淵積憲鹹 (醖糧築夢廠網鏇襯顧製 )	积极	2015-09-17
				Sitagliptin 100 mg